Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Related AZN
AstraZeneca Falls More Than 5% Following Q4 Print
Earnings Scheduled For February 4, 2016
AstraZeneca Q4 product sales down 7%; net income up 221%; CF Ops off 69%; guidance lowered; shares down 6% premarket (Seeking Alpha)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

Jan 2016Oddo SecuritiesUpgradesNeutralTop Pick
Jan 2016BarclaysUpgradesUnderweightEqual-weight
Dec 2015Morgan StanleyUpgradesUnderweightOverweight

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings


Related Articles (AZN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters